Search results
Showing 7456 to 7470 of 7707 results
This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.
Discontinued [GID-TA10072]
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued [GID-TA10066]
Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]
Discontinued [GID-TA10047]
Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]
Discontinued [GID-TA10045]
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
In development [GID-TA11357] Expected publication date: TBC
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued [GID-TAG321]
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued [GID-TAG300]
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued [GID-TAG278]
Discontinued [GID-TAG368]
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
Discontinued [GID-TA10242]
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued [GID-TA11209]
In development [GID-TA11472] Expected publication date: TBC
This guidance has been updated and replaced by NICE interventional procedures guidance 795.